<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04695522</url>
  </required_header>
  <id_info>
    <org_study_id>CVSR0006</org_study_id>
    <nct_id>NCT04695522</nct_id>
  </id_info>
  <brief_title>ADR-002K for Patients With Ischemic Cardiomyopathy Who Undergo Coronary Artery Bypass Surgery</brief_title>
  <official_title>Phase I Trial of ADR-002K for Patients With Ischemic Cardiomyopathy Who Undergo Coronary Artery Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rohto Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Osaka University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ischemic cardiomyopathy undergoing coronary artery bypass surgery&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse event</measure>
    <time_frame>26 weeks</time_frame>
    <description>Safety assessment related to adverse events and this product</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of change in late gadolinium contrast-enhanced area at the time of screening and 6 months after surgery</measure>
    <time_frame>26 weeks</time_frame>
    <description>Efficacy (Exploratory)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of complication associated with drug administration method</measure>
    <time_frame>26 weeks</time_frame>
    <description>Feasibility of drug administration method</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>D017202</condition>
  <arm_group>
    <arm_group_label>Group of subjects undergoing cell transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group of subjects undergoing sham operation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ADR-002K administration</intervention_name>
    <description>ADR-002K administration</description>
    <arm_group_label>Group of subjects undergoing cell transplantation</arm_group_label>
    <arm_group_label>Group of subjects undergoing sham operation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who are clinically diagnosed with ischemic cardiomyopathy and receive CABG&#xD;
&#xD;
          2. Patients with a left ventricular ejection fraction of 40% or less by cardiac&#xD;
             ultrasonography within 4 weeks before obtaining consent&#xD;
&#xD;
          3. Others&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have a combination of cardiovascular disease such as severe organic&#xD;
             valvular disease or aortic aneurysm determined by investigator or co-investigator to&#xD;
             affect clinical trial procedure&#xD;
&#xD;
          2. Patients whose participation in a clinical trial is considered inappropriate at the&#xD;
             discretion of the investigator or co-investigator&#xD;
&#xD;
          3. Others&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daisuke Mori, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osaka University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daisuke Mori, Ph.D</last_name>
    <phone>+81-6-6879-3154</phone>
    <email>daimolion@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Masao Sasai, Ph.D</last_name>
    <phone>+81-6-6879-3154</phone>
    <email>sasai-masao@tissue.med.osaka-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>5650871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daisuke Mori, Ph.D</last_name>
      <phone>+81-6-6879-3154</phone>
      <email>daimolion@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Masao Sasai, Ph.D</last_name>
      <phone>+81-6-6105-5240</phone>
      <email>sasai-masao@tissue.med.osaka-u.ac.jp</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 2, 2021</last_update_submitted>
  <last_update_submitted_qc>January 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Osaka University</investigator_affiliation>
    <investigator_full_name>Daisuke Mori</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Coronary artery bypass</keyword>
  <keyword>Ischemic cardiomyopathy</keyword>
  <keyword>Adipose-derived mesenchymal stem cells</keyword>
  <keyword>Regenerative medicine</keyword>
  <keyword>Spray method</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

